Itau Unibanco Holding S.A. Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Itau Unibanco Holding S.A. purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the second quarter, Holdings Channel.com reports. The fund purchased 27,000 shares of the company’s stock, valued at approximately $453,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at about $43,000. Sound Income Strategies LLC boosted its position in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares during the period. Banque Cantonale Vaudoise bought a new position in Teva Pharmaceutical Industries during the first quarter worth about $74,000. Brooklyn Investment Group increased its stake in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after purchasing an additional 4,014 shares in the last quarter. Finally, CWM LLC raised its position in shares of Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after purchasing an additional 767 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.6%

TEVA opened at $25.40 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $26.38. The firm has a market capitalization of $29.13 billion, a P/E ratio of -158.73, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70. The company has a fifty day moving average price of $20.39 and a 200-day moving average price of $18.24.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $4.48 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company earned $0.69 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $25.86.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.